Cullinan Therapeutics, Inc.(CGEM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
CGEM Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Cullinan Therapeutics, Inc. (CGEM), a Healthcare sector company. CGEM is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of CGEM by reported 13-F value include MPM BioImpact, Lynx1 Capital Management, BVF, based on the most recent SEC filings. CGEM trades on the Nasdaq exchange and files with the SEC under CIK 1789972. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGEM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cullinan Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-53.7M
ROIC
Q2 2026
-71.2%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
-31.4% YoYOperating Income
-22.7% YoYEPS (Diluted)
Total Assets
-27.9% YoYOp. Cash Flow
-21.0% YoYFree Cash Flow
-21.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 -100.0% | $18.9M | $0.00 |
| Net Income | $-219.9M -31.4% | $-167.4M -9.3% | $-153.2M -237.7% | $111.2M +269.6% | $-65.6M -26.6% | $-51.8M |
| Operating Income | $-241.6M -22.7% | $-196.9M -3.1% | $-191.1M -232.1% | $144.6M +312.9% | $-68.0M -12.6% | $-60.3M |
| EPS (Diluted) | — | — | $-3.69 -255.0% | $2.38 +256.6% | $-1.52 | — |
| Total Assets | $448.4M -27.9% | $621.8M +28.4% | $484.2M -13.7% | $561.1M +28.3% | $437.2M +103.6% | $214.7M |
| Operating Cash Flow | $-175.8M -21.0% | $-145.3M -8.2% | $-134.3M -6.0% | $-126.7M -191.6% | $-43.4M -45.9% | $-29.8M |
| Free Cash Flow | $-175.8M -21.0% | $-145.3M -8.0% | $-134.5M -5.2% | $-127.8M -194.2% | $-43.4M -45.8% | $-29.8M |
Get alerted when CGEM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cullinan Therapeutics, Inc. including:
Top Institutional Holders of CGEM
MPM BioImpact LLC
$177.2M9,731,341 shLynx1 Capital Management LP
$163.2M8,963,500 shBVF INC/IL
$104.7M5,750,683 shBlackRock, Inc.
$95.3M5,232,766 shPRICE T ROWE ASSOCIATES INC /MD/
$69.7M3,825,950 shSTATE STREET CORP
$66.8M3,668,627 shKynam Capital Management, LP
$56.7M3,114,132 shVANGUARD CAPITAL MANAGEMENT LLC
$47.6M2,614,066 shRTW INVESTMENTS, LP
$43.1M2,364,347 shSiren, L.L.C.
$34.5M1,893,410 sh
| Fund | Value | Shares |
|---|---|---|
| MPM BioImpact LLC | $177.2M | 9,731,341 |
| Lynx1 Capital Management LP | $163.2M | 8,963,500 |
| BVF INC/IL | $104.7M | 5,750,683 |
| BlackRock, Inc. | $95.3M | 5,232,766 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $69.7M | 3,825,950 |
| STATE STREET CORP | $66.8M | 3,668,627 |
| Kynam Capital Management, LP | $56.7M | 3,114,132 |
| VANGUARD CAPITAL MANAGEMENT LLC | $47.6M | 2,614,066 |
| RTW INVESTMENTS, LP | $43.1M | 2,364,347 |
| Siren, L.L.C. | $34.5M | 1,893,410 |
More Healthcare Companies
View all Healthcare →Put CGEM on your watchlist
Track score changes the day Cullinan Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is CGEM a good stock to buy?
13F Pro's AI-powered analysis of Cullinan Therapeutics, Inc. (CGEM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CGEM are available on the CGEM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. CGEM is classified as a small company.
Which hedge funds own CGEM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CGEM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cullinan Therapeutics, Inc.'s investment landscape.